Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. FDA releases September 2016 510(k) clearances
The FDA released the full list of 510(k) clearances it granted for September 2016. Read more
4. Appeals court denies inventor in patent spat with Endologix pickup TriVascular
A federal appeals court yesterday upheld a lower court’s ruling on the claim construction in a patent infringement dispute between the inventor of a vascular stent patent and Endologix acquisition TriVascular Technologies.
In February, the U.S. Court of Appeals for the Federal Circuit upheld a Patent Trial & Appeal Board ruling that the patent was not invalid due to obviousness. The appeals court found that TriVascular didn’t demonstrate that the patent, held by Shaun Samuels, was invalid because of obviousness, nor did they find that the board was in error in its claims construction process, according to court documents. Read more
3. Baxter CEO Almeida on creating a bridge between invention and innovation
“The part that separates most companies regarding innovation, those that truly get it, is the bridge between the invention and the innovation,” Baxter chairman & CEO Joe Almeida said last week at the annual Cleveland Clinic Medical Innovation Summit.
The ability to bring innovation or an invention to the world is what distinguishes companies that offer health outcomes. “The ability to create value in healthcare and access is quite significant.” Read more
2. Boston Scientific extends $210 million tender offer for EndoChoice
Boston Scientific said today that it’s extending its $210 million tender offer for EndoChoice and its line of devices for treating gastrointestinal disease.
The $8-per-share tender offer was slated to expire at midnight Nov. 4. Marlborough, Mass.-based Boston Scientific said it’s moving the deadline out to Nov. 21 “to allow additional time for the satisfaction of the conditions of the offer.” Some 66.5% of outstanding EndoChoice shares had been tendered as of yesterday, the company said. Read more
1. Abbott looks to mollify EU regulators on St. Jude Medical merger; sues Alere for breach of contract
Abbott made moves yesterday on a pair of pending, multi-billion-dollar acquisitions, its $25 billion merger with St. Jude Medical and a $6 billion union with Alere.
The European Commission said Abbott, which along with St. Jude agreed to deal some of its vascular assets to Japan’s Terumo Corp. last month, agreed to make unspecified concessions to win over anti-trust regulators there. That pushes the deadline back for the commission’s ruling on the deal, from the prior cutoff of Nov. 9 to Nov. 21. The merger, announced in April, is slated to close by the end of this year. Read more
